Technical Analysis for IBIO - iBio, Inc.

Grade Last Price % Change Price Change
grade F 0.2349 -2.93% -0.01
IBIO closed down 2.93 percent on Friday, January 17, 2020, on 48 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Down
Historical IBIO trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish -2.93%
Spinning Top Other -2.93%
Wide Bands Range Expansion -2.93%
Oversold Stochastic Weakness -2.93%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.34%
Narrow Range Bar Range Contraction 5.34%
NR7 Range Contraction 5.34%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

iBio, Inc., a biotechnology company, engages in the development and commercialization of vaccines and therapeutic proteins through its proprietary iBioLaunch platform technology in the United States. Its product portfolio includes seasonal and H1N1 influenza vaccines for the seasonal influenza virus strains; pandemic avian influenza vaccine for the pathogenic avian influenza viruses; and therapeutic vaccines for human papilloma virus. The company also offers biodefense products, including oral anthrax booster vaccine candidates and candidate plague vaccines. In addition, it provides therapeutic protein product candidates comprising human alpha-galactosidase A for the treatment of Fabry disease; human C-1 esterase inhibitor for the treatment of hereditary angioedema; and human alpha-1 antitrypsin for treatment of disorders caused by a deficiency of alpha-1 antitrypsin. Further, the company offers vaccine enhancements through its iBioModulator platform. It has a license and collaboration agreement with Caliber Biotherapeutics, LLC for the development and production of recombinant plant-based biopharmaceuticals. The company is headquartered in Newark, Delaware.
Medicine Biotechnology Disorders Influenza Vaccination Microbiology Vaccines Biopharmaceuticals Hereditary Angioedema Seasonal Influenza Fabry Disease H5n1 Clinical Trials Deficiency Human Papilloma Virus Influenza Vaccines Treatment Of Fabry Disease

Is IBIO a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 1.4
52 Week Low 0.05
Average Volume 6,794,496
200-Day Moving Average 0.56
50-Day Moving Average 0.21
20-Day Moving Average 0.25
10-Day Moving Average 0.25
Average True Range 0.04
ADX 16.47
+DI 23.12
-DI 21.39
Chandelier Exit (Long, 3 ATRs ) 0.23
Chandelier Exit (Short, 3 ATRs ) 0.31
Upper Bollinger Band 0.30
Lower Bollinger Band 0.21
Percent B (%b) 0.32
BandWidth 35.82
MACD Line 0.00
MACD Signal Line 0.01
MACD Histogram -0.0047
Fundamentals Value
Market Cap 21.8 Million
Num Shares 92.8 Million
EPS -0.16
Price-to-Earnings (P/E) Ratio -1.43
Price-to-Sales 74.56
Price-to-Book 3.17
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.26
Resistance 3 (R3) 0.27 0.26 0.26
Resistance 2 (R2) 0.26 0.25 0.26 0.26
Resistance 1 (R1) 0.25 0.25 0.24 0.24 0.26
Pivot Point 0.24 0.24 0.24 0.24 0.24
Support 1 (S1) 0.23 0.23 0.22 0.23 0.21
Support 2 (S2) 0.22 0.23 0.22 0.21
Support 3 (S3) 0.21 0.22 0.21
Support 4 (S4) 0.21